Related Experiment Video

Updated: Jul 2, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer

Tong Sun1, Yifeng Zhou, Ming Yang

  • 1Department of Etiology and Carcinogenesis, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Cancer Research
|September 2, 2008
PubMed

Insights

Genetic variations in cytotoxic T-lymphocyte antigen 4 (CTLA-4) influence cancer risk. The CTLA-4 49G>A polymorphism increases susceptibility to multiple cancers by affecting T-cell activation.

Area of Science:

  • Immunology
  • Genetics
  • Oncology

Background:

  • Antitumor T lymphocytes are crucial for cancer immunosurveillance.
  • Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a key negative regulator of T-cell responses.
  • Genetic variations in immune regulatory genes may impact cancer susceptibility.

Purpose of the Study:

  • To investigate the association between genetic polymorphisms in CTLA-4 and cancer susceptibility.
  • To explore the functional impact of identified CTLA-4 polymorphisms on T-cell activity.

Main Methods:

  • A two-stage study employing haplotype-tagging single nucleotide polymorphism (SNP) analysis.
  • Multiple independent case-control analyses involving over 11,000 individuals.
  • Biochemical assays to assess the functional effects of CTLA-4 variants.

Main Results:

  • The CTLA-4 49G>A polymorphism, leading to an alanine to threonine substitution, was significantly associated with increased risk for lung, breast, esophagus, and gastric cardia cancers.
  • Individuals with the CTLA-4 49AA genotype exhibited a 1.72-fold higher odds of developing cancer (P = 3.4 x 10(-7)).
  • The CTLA-4 (17)Thr variant demonstrated enhanced binding to B7.1 and stronger T-cell inhibition compared to (17)Ala, resulting in reduced T-cell activation and proliferation in 49AA genotype carriers.

Conclusions:

  • Genetic polymorphisms in CTLA-4, specifically the 49G>A variant, are linked to increased susceptibility to various cancers.
  • The functional impact of this polymorphism on T-cell regulation provides a mechanistic explanation for its association with cancer risk.
  • These findings highlight the role of immune gene polymorphisms in cancer development and offer potential targets for immunotherapeutic strategies.

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology11:20

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...